Profound Bio - About the company
Profound Bio is an acquired company based in Woodinville (United States), founded in 2018. It operates as a Developer of novel therapies for the treatment of cancer. Profound Bio has raised $250M in funding from investors like Orbimed, RA Capital Management and Nextech Invest, with last known valuation of $*****. The company has 3305 active competitors, including 1124 funded and 779 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of novel therapies for the treatment of cancer. The company is involved in the development of CMC for antibody-drug conjugates that kill tumor cells, promote cell rejuvenation, stimulates collagen production and prevents collagen degrading, and more.
- Website
- profoundbio.com
- Email ID
- *****@profoundbio.com
Key Metrics
Founded Year
2018
Location
Woodinville, United States
Stage
Acquired
Total Funding
$250M in 3 rounds
Latest Funding Round
Last Known Valuation
$***** as on Apr 03, 2024
Ranked
288th among 3305 active competitors
Similar Companies
Exit Details
Acquired by Genmab (Apr 03, 2024)
Legal entities associated with Profound Bio
Profound Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ProfoundBio US Co CIN: 3038853 , United States, Active | Jun 08, 2020 | - | - | - |
Profound Bio's acquisition details
Click here to take a look at Profound Bio's acquisition in detail
Sign up to download Profound Bio's company profile
Profound Bio's funding and investors
Profound Bio has raised a total funding of $250M over 3 rounds. Its first funding round was on Jul 12, 2021. Its latest funding round was a Series B round on Feb 13, 2024 for $*****. 14 investors participated in its latest round. Profound Bio has 20 institutional investors.
Here is the list of recent funding rounds of Profound Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 13, 2024 | 4733410 | Series B | 6393831 | 1804645 | 4756175 | 3402584 |
Jun 02, 2022 | 4402805 | Series A | 5815883 | 3497167 | 8716884 | |
Jul 12, 2021 | 6145258 | Series A | 8917254 | 3592038 |
Access funding benchmarks and valuations. Sign up today!View details of Profound Bio's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Profound Bio's Competitors and alternates
Top competitors of Profound Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Profound Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
288th |  Profound Bio 2018, Woodinville (United States), Acquired | Developer of novel therapies for the treatment of cancer | $250M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Profound Bio's competitors? Click here to see the top ones
Profound Bio's Investments and acquisitions
Profound Bio has made no investments or acquisitions yet.
Reports related to Profound Bio
Here is the latest report on Profound Bio's sector:
News related to Profound Bio
Filter this listMedia has covered Profound Bio for 1 event in last 1 year.
•
Genmab halts enrollment for cancer drug from ProfoundBio buyoutEndpoints•Jan 26, 2026•Profound Bio, Genmab
•
•
•
Danish Biotech Giant Genmab to Acquire ProfoundBio for $1.8 BillionCaixin Global•Apr 06, 2024•Genmab, Profound Bio, AbbVie, DARZALEX and 2 others
•
•
Profoundbio seeks to grow the Seattle equipment after a 9 -digit financing roundesdelatino.com•Feb 20, 2024•Profound Bio
•
Capitalizing on ADC frenzy, ProfoundBio attracts $112M oversubscribed series BFierce Biotech•Feb 12, 2024•Profound Bio, LAV Asset Management, RA Capital Management, Orbimed and 12 others
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Profound Bio
Explore our recently published companies
- Salmonandsable - Unfunded company
- Order Asprigofthymesrq - Unfunded company
- Pizzatupwalthamabbey - United Kingdom based, Unfunded company
- Damascusbakeryandsweets - United Kingdom based, Unfunded company
- Alifishandchips - United Kingdom based, Unfunded company
- Pasam Pizza Kebab - Germany based, Unfunded company
